Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
Provided By GlobeNewswire
Last update: Mar 10, 2025
GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading global contract research, development, and manufacturing organization, for a total value of $36.5 million. The Bayview site includes manufacturing, laboratory, warehousing and office space, and is fitted with multiple monoclonal antibody (mAbs) manufacturing lines.
Read more at globenewswire.com4.72
+0.18 (+3.96%)
Find more stocks in the Stock Screener
EBS Latest News and Analysis
7 days ago - ChartmillTuesday's after hours session: top gainers and losersAs the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
